Question 1

What is PT-141 (Bremelanotide)?

Accepted Answer

PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist that is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the only FDA-approved peptide that works through the central nervous system to address sexual dysfunction.

Question 2

What are the research benefits of PT-141 (Bremelanotide)?

Accepted Answer

Research on PT-141 (Bremelanotide) has investigated its potential effects in several areas, including: FDA-approved for HSDD in premenopausal women (Vyleesi); Works through CNS melanocortin pathways (not vascular); Studied for both male and female sexual dysfunction; Only peptide FDA-approved for sexual function. These findings are primarily from preclinical and animal studies unless otherwise noted. Results may not translate directly to humans.

Question 3

How does PT-141 (Bremelanotide) work?

Accepted Answer

PT-141 activates melanocortin receptors MC3R and MC4R in the hypothalamus, the brain region that regulates sexual behavior and arousal. This central mechanism of action distinguishes it from vascular-based treatments. It does not directly affect blood flow but rather modulates the neural pathways involved in sexual desire and arousal.

Question 4

What is the FDA/legal status of PT-141 (Bremelanotide)?

Accepted Answer

PT-141 (Bremelanotide) is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is available for research use only. It has not been evaluated for safety or efficacy in humans by regulatory agencies. Always consult applicable laws in your jurisdiction before purchase or use.

Question 5

What are the known risks or side effects of PT-141 (Bremelanotide)?

Accepted Answer

Based on available research, PT-141 (Bremelanotide) has been associated with the following in study settings: Nausea (most common, ~40% in trials); Facial flushing; Injection site reactions; Transient blood pressure elevation. Long-term safety data in humans is limited or absent for most research peptides. This should not be taken as a complete safety profile.

Question 6

Where can I find published research on PT-141 (Bremelanotide)?

Accepted Answer

Published research on PT-141 (Bremelanotide) can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for "PT-141 (Bremelanotide)" or its aliases (Bremelanotide, Vyleesi) to find peer-reviewed studies. PEP.WIKI aggregates key studies with abstracts and study type classifications on each compound's research page.

PT-141 (Bremelanotide)

Overview

Mechanism of Action

Key Research Benefits

Clinical Evidence Summary

Key Studies / PubMed References

Targeting the central melanocortin system for the treatment of metabolic disorders.

Medical Treatment of Female Sexual Dysfunction.

Bremelanotide for Treatment of Female Hypoactive Sexual Desire.

Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.

Bremelanotide: First Approval.

Side Effects & Safety

Known Interactions

Frequently Asked Questions

Research Disclaimer